Malaria vaccine candidate, RTS,S reduces the risk of malaria by half in African children
First results from a large-scale Phase III trial of RTS,S*, published online today in the New England Journal of Medicine (NEJM), show the malaria vaccine candidate to provide young African children with significant protec ...
Diseases, Conditions, Syndromes
Oct 18, 2011 |
not rated yet |
1
FDG-PET appears promising for predicting prognosis of patients with inoperable NSCLC
The prognosis for patients with stage II and III inoperable non-small cell lung cancer (NSCLC) is poor, with only about 15 percent of patients surviving at five years post-treatment for the disease. While new treatment strategies ...
Cancer
Oct 05, 2011 |
not rated yet |
0
Company stock prices before public announcements of oncology trial results
Prior knowledge of phase III clinical trials of new drugs and Food and Drug Administration (FDA) regulatory decisions may affect the price of a drug company's stock according to a study published September 26 in the Journal of ...
Other
Sep 26, 2011 |
not rated yet |
0
New hope for advanced post-menopausal breast cancer patients resistant to hormonal therapy
Results from a phase III clinical trial have shown that combining two existing cancer drugs to treat post-menopausal women with advanced breast cancer resistant to hormonal therapy significantly improves outcome. Researchers ...
Cancer
Sep 26, 2011 |
not rated yet |
0
Bone-strengthening drug gives pain relief in prostate cancer bone metastases
Stockholm, Sweden: Many prostate cancer patients develop bone metastases, and controlling the pain these cause can be difficult. Now the first large randomised Phase III trial of a bisphosphonate drug in these patients has ...
Cancer
Sep 25, 2011 |
4 / 5 (1) |
0
Infusing chemotherapy into the liver gives extra months of disease-free life in melanoma patients
Melanoma of the eye (ocular or uveal melanoma) frequently spreads to the liver and, once this has happened, there is no effective treatment and patients die within an average of two to four months. Only about one in ten patients ...
Cancer
Sep 23, 2011 |
4 / 5 (1) |
0
First Phase III trial of an alpha-pharmaceutical
Until recently, options for patients with bone metastases from advanced prostate cancer have been very limited. But now the first Phase III study of an alpha-pharmaceutical in these patients has shown that it can prolong ...
Cancer
Sep 23, 2011 |
not rated yet |
0
